Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 434Carcinoma, Non-Small-Cell Lung 360Neoplasms 339Prostatic Neoplasms 276Colorectal Neoplasms 264Multiple Myeloma 206Lung Neoplasms 195Neoplasm Metastasis 179Leukemia, Myeloid, Acute 160Ovarian Neoplasms 155Pancreatic Neoplasms 152Squamous Cell Carcinoma of Head and Neck 138Melanoma 126Recurrence 104Head and Neck Neoplasms 99Glioblastoma 99Carcinoma, Renal Cell 98Endometrial Neoplasms 96Carcinoma, Hepatocellular 93Lymphoma, Non-Hodgkin 92Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Lymphoma 91Triple Negative Breast Neoplasms 90Stomach Neoplasms 88Uterine Cervical Neoplasms 85Brain Neoplasms 85Lymphoma, Large B-Cell, Diffuse 80Urinary Bladder Neoplasms 77Glioma 74Leukemia, Lymphocytic, Chronic, B-Cell 73

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Granulosa cell tumor of the ovary × 30 days × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡